The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups ... such as Procter & Gamble and GSK were among several accused in lawsuits ...

GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist ...

GlaxoSmithKline found that the cups for Children's Robitussin Honey cough syrup were missing lines for the 5-milliliter and 10-milliliter graduations and the cups for Children's Dimetapp were ...

A panel last year said it found evidence the ingredient, used in many popular medicines, did not aid with nasal congestion.

The above news is likely to benefit GSK plc GSK, which is evaluating its own investigational chronic cough drug in late-stage development. The drug, named camlipixant, was added by GSK after it ...

Another chronic cough therapy in the late stage of development is GSK’s camlipixant, a twice-daily oral P2X3 receptor antagonist. GSK added the drug to its portfolio as part of the $2bn ...